Transcriptional suppression of microRNA-27a contributes to laryngeal cancer differentiation via GSK-3β-involved Wnt/β-catenin pathway

Sheng Chen; Yuan-Yuan Sun; Zhao-Xiong Zhang; Yun-Hui Li; Zhen-Ming Xu; Wei-Neng Fu

doi:10.18632/oncotarget.14769

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Transcriptional suppression of microRNA-27a contributes to laryngeal cancer differentiation via GSK-3β-involved Wnt/β-catenin pathway

Sheng Chen, Yuan-Yuan Sun, Zhao-Xiong Zhang, Yun-Hui Li, Zhen-Ming Xu and Wei-Neng Fu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:14708-14718. https://doi.org/10.18632/oncotarget.14769

Metrics: PDF 1920 views | HTML 2385 views | ?

Abstract

Sheng Chen1, Yuan-Yuan Sun1, Zhao-Xiong Zhang1, Yun-Hui Li2, Zhen-Ming Xu3, Wei-Neng Fu1

1Department of Medical Genetics, China Medical University, Shenyang, 110122, P.R. China

2Department of Laboratory Medicine, No. 202 Hospital of PLA, Shenyang, 110003, P.R. China

3Department of Otolaryngology, No. 463 Hospital of PLA, Shenyang, 110007, P.R. China

Correspondence to:

Yun-Hui Li, email: [email protected]

Zhen-Ming Xu, email: [email protected]

Wei-Neng Fu, email: [email protected]

Keywords: laryngeal cancer, miR-27a, ATRA, differentiation, GSK-3β

Received: November 04, 2016 Accepted: January 11, 2017 Published: January 20, 2017

ABSTRACT

miR-27a regulates cell differentiation in a variety of diseases. However, whether and how miR-27a participates in laryngeal cancer cell differentiation remains unknown. Therefore, we explored role and molecular mechanism of miR-27a in laryngeal cancer differentiation in the study. We found that miR-27a expression was inversely correlated with laryngeal cancer differentiation degree based on the clinical pathological diagnosis of each patient. miR-27 asignificantly rescued differentiation and inhibited β-catenin, LEF1, OCT4 and SOX2 in Wnt/β-catenin pathway in all-trans-retinoic acid (ATRA)-induced laryngeal cancer cells. Bindings of RARα to miR-27a and miR-27a to GSK-3β were confirmed by ChIP and Luciferase reporter assays, respectively. In conclusion, miR-27a is a negative regulator in laryngeal cancer differentiation. RARα-mediated miR-27a transcriptional inactivation releases the inhibition of miR-27a on GSK-3β leading to laryngeal cancer differentiation through GSK-3β-involved Wnt/β-catenin pathway, suggesting that miR-27a is a usefully therapeutic target at least in ATRA-induced laryngeal cancer differentiation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14769

Publication Alerts

Research Papers:

Transcriptional suppression of microRNA-27a contributes to laryngeal cancer differentiation via GSK-3β-involved Wnt/β-catenin pathway

Abstract